| Literature DB >> 28293318 |
Inas R El-Alameey1, Hanaa H Ahmed2, Sawsan M Tawfik1, Fawzia Hassaballa1, Ayman M Abdel Gawad1, Eman Eltahlawy3.
Abstract
BACKGROUND: Gastrointestinal symptoms are a common feature in infants with congenital heart disease. AIM: This study was designed to evaluate age-dependent serum levels of antigliadin antibodies among malnourished Egyptian infants with congenital heart disease (CHD) and gastrointestinal symptoms. SUBJECTS AND METHODS: This case-control study conducted on 60 infants with established congenital heart disease. They were subdivided into cyanotic and acyanotic groups, and each group includes 30 patients compared with thirty apparently healthy infants of matched age, sex, and social class. Serum antigliadin antibodies levels were measured using ELISA.Entities:
Keywords: Congenital Heart; Gluten Sensitivity; Infants
Year: 2017 PMID: 28293318 PMCID: PMC5320909 DOI: 10.3889/oamjms.2017.026
Source DB: PubMed Journal: Open Access Maced J Med Sci ISSN: 1857-9655
Clinical findings of the studied patients
| Variables | No (%) | Variables | No (%) |
|---|---|---|---|
| Male | 26 (43.3%) | Pallor | 44 (73.3%) |
| Female | 34 (56.7%) | ||
| Positive consanguinity | 24 (40 %) | Rickets | 34 (56.7%) |
| Diarrhea | 58 (96.7%) | Repeated chest infections | 12 (20%) |
| Vomiting | 26 (43.3%) | Anti-heart failure medications | 30 (50%) |
| Abdominal pain | 38 (63.3%) | Abdominal distension | 14 (23.3%) |
Comparison of anthropometric measures of the studied patients, and control groups
| Variables | Total Patients N=60 | Cyanotic subgpI n=30 | Acyanotic subgpII n=30 | Control Group N=30 | subgpI versus subgpII | Total patients versus controls |
|---|---|---|---|---|---|---|
| Mean ±SD | Mean ±SD | Mean ±SD | Mean ±SD | P value | P value | |
| Occipitofrontal circumference(cm) | 42.93±3.59 | 41.53±3.86 | 44.33±2.76 | 46.4±3.55 | 0.03 | 0.002 |
| Mid-arm circumference(cm) | 12.2±1.66 | 11.43±1.69 | 12.97±1.27 | 13.49±0.9 | 0.002 | 0.003 |
| Mid-chest circumference(cm) | 44.0±4.38 | 43.27±5.2 | 44.73±3.42 | 49.85±3.31 | 0.32 | 0.000 |
| Weight for age z-score | -2.55±1.27 | -3.18±0.9 | -2.02±1.29 | -0.25±0.42 | 0.003 | 0.000 |
| Height for age z-score | -2.62±1.4 | -3.07±1.28 | -2.38±1.35 | 0.25±0.55 | 0.107 | 0.000 |
| Wt for Ht z score | -0.75±1.0 | -1.34±0.88 | -0.28±1.07 | -0.24±0.65 | 0.001 | 0.03 |
Significant difference at p<0.05,
highly significant difference at p<0.005.
Comparison of laboratory findings of the studied patients, and control groups
| Variables | Cyanotic subgroup I n=30 | Acyanotic subgroup II n=30 | Control Group N=30 | ANOVA | |
|---|---|---|---|---|---|
| Mean ±SD | Mean ±SD | Mean ±SD | F | P | |
| Serum antigliadin IgA (IU/ml) | 151.95±59.4 | 150.81±27.84 | 92.07±2.67 | 104.17 | 0.000 |
| Serum antigliadin IgG (IU/ml) | 111.95±109.83 | 142.16±138.57 | 70.77±17.51 | 1.4 | 0.251 |
| Serum antigliadin IgM (IU/ml) | 3.9±2.63 | 2.8±1.52 | 1.1± 0.33 | 431.96 | 0.00 |
| Serum calcium (mg/dl) | 8.35±0.23 | 8.46± 0.52 | 9.38±0.29 | 31.35 | 0.00 |
| Serum alkaline phosphatase (IU/l) | 336.53±84.1 | 380.71±110.56 | 106.4±14.38 | 66.702 | 0.00 |
| HB (gm/dl) | 13.78 ± 1.8 | 11.54 ± 1.7 | 13.05 ± 0.77 | 5.495 | 0.007 |
| Serum iron (mcg/dl) | 40.56±8.03 | 33.40±6.10 | 73.5±8.75 | 138.22 | 0.00 |
| Serum TIBC (mcg/dl) | 432.0±14.52 | 388.53±37.44 | 285.4±27.4 | 109.28 | 0.00 |
Significant difference at p<0.05,
highly significant difference at p<0.005.
Correlations between weight and height for age z-score, some laboratory measures and serum antigliadin antibodies of the studied patients
| Variables | Weight/age z-score | Height / age z-score | Serum calcium | Serum alkaline phosphatase |
|---|---|---|---|---|
| Serum antigliadin IgM (IU/ml) | -0.107 | -0.265 | -0.331 | 0.117 |
| Serum antigliadin IgG (IU/ml) | -0.261 | 0.111 | 0.189 | 0.292 |
| Serum antigliadin IgA (IU/ml) | 0.105 | 0.162 | 0.031 | 0.036 |
Significant difference at p<0.05,
highly significant difference at p<0.005.
Univariate analysis between GIT symptoms and serum antigliadin IgA antibodies levels in the studied patients
| Covariates | Serum antigliadin antibodies (IgA) | ||||
|---|---|---|---|---|---|
| High 26 (60%) | Normal 34 (40%) | P value | Odd ratio (95% CI) | ||
| No % | No % | ||||
| Age at onset of symptoms | Before 6 month | 8 (30.8%) | 22 (64.7%) | 0.04 | 4.13 (0.88,19.27) |
| Diarrhea | Negative | 4 (15.4%) | 26 (76.5%) | 0.02 | 0.06 (0.01, 0.37) |
| Abdominal pain | Positive | 20 (76.9%) | 22 (64.7%) | 0.01 | 0.55 (0.11, 2.80) |
| Abdominal distension | Positive | 20 (76.9%) | 10 (29.4%) | 0.01 | 0.13 (0.02, 0.66) |
Significant difference at p < 0.05,
highly significant difference at p < 0.005. Gastrointestinal symptoms (GIT).
Univariate analysis between GIT symptoms and serum antigliadin IgG antibodies levels in the studied patients
| Covariates | Serum antigliadin antibodies (IgG) | ||||
|---|---|---|---|---|---|
| High 12 (20%) | Normal 48 (80%) | P value | Odd ratio (95% CI) | ||
| No % | No % | ||||
| Age at onset of symptoms | Before 6 month | 16 (38.1%) | 14 (77.8%) | 0.04 | 5.69 (0.94, 34.46) |
| Diarrhea | Negative | 0 (0%) | 30 (62.5%) | 0.02 | 0.06 (0.01, 0.37) |
| Abdominal pain | Positive | 10 (83.3%) | 32 (66.7%) | 0.01 | 0.55 (0.11, 2.80) |
| Abdominal distension | Positive | 12 (100%) | 18 (37.5%) | 0.01 | 0.13 (0.02, 0.66) |
Significant difference at p < 0.05,
highly significant difference at p < 0.005. Gastrointestinal symptoms (GIT).
Univariate analysis between GIT symptoms and serum antigliadin IgM antibodies levels in the studied patients
| Covariates | Serum antigliadin antibodies (IgM) | ||||
|---|---|---|---|---|---|
| High 42 (70%) | Normal 18 (30%) | P value | Odd ratio (95% CI) | ||
| No % | No % | ||||
| Age at onset of symptoms | Before 6 month | 20 (38.1%) | 14 (77.8%) | 0.04* | 5.69 (0.49, 4.46) |
| Diarrhea | Negative | 20 (47.6%) | 10 (55.6%) | 0.60 | 0.73 (0.15, 3.49) |
| Abdominal pain | Positive | 10 (83.3%) | 2 (11.1%) | 0.00** | 0.01 (0.00, 0.11) |
| Abdominal distension | Positive | 26 (61.9%) | 4 (22.2%) | 0.04* | 0.18 (0.03, 1.07) |